Review



exosome human isolation reagent  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Bio-Techne corporation exosome human isolation reagent
    Exosome Human Isolation Reagent, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 123 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exosome human isolation reagent/product/Bio-Techne corporation
    Average 95 stars, based on 123 article reviews
    exosome human isolation reagent - by Bioz Stars, 2026-05
    95/100 stars

    Images



    Similar Products

    anti cd81  (Novus Biologicals)
    94
    Novus Biologicals anti cd81
    Anti Cd81, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd81/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    anti cd81 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    anti cd8  (Novus Biologicals)
    94
    Novus Biologicals anti cd8
    Anti Cd8, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd8/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    anti cd8 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    cytotoxic t cell marker cd8  (Novus Biologicals)
    94
    Novus Biologicals cytotoxic t cell marker cd8
    Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases <t>CD8-positive</t> ​T cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A) Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D) the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample. * p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
    Cytotoxic T Cell Marker Cd8, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cytotoxic t cell marker cd8/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    cytotoxic t cell marker cd8 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    monoclonal anti cd81  (Novus Biologicals)
    94
    Novus Biologicals monoclonal anti cd81
    Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases <t>CD8-positive</t> ​T cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A) Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D) the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample. * p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
    Monoclonal Anti Cd81, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal anti cd81/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    monoclonal anti cd81 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    cd81  (Novus Biologicals)
    94
    Novus Biologicals cd81
    Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases <t>CD8-positive</t> ​T cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A) Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D) the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample. * p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
    Cd81, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd81/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    cd81 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    exosome human isolation reagent  (Bio-Techne corporation)
    95
    Bio-Techne corporation exosome human isolation reagent
    Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases <t>CD8-positive</t> ​T cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A) Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D) the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample. * p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
    Exosome Human Isolation Reagent, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exosome human isolation reagent/product/Bio-Techne corporation
    Average 95 stars, based on 1 article reviews
    exosome human isolation reagent - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    antibodies against cd81  (Bio-Techne corporation)
    95
    Bio-Techne corporation antibodies against cd81
    Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases <t>CD8-positive</t> ​T cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A) Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D) the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample. * p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
    Antibodies Against Cd81, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against cd81/product/Bio-Techne corporation
    Average 95 stars, based on 1 article reviews
    antibodies against cd81 - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases CD8-positive ​T cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A) Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D) the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample. * p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).

    Journal: Neoplasia (New York, N.Y.)

    Article Title: Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer

    doi: 10.1016/j.neo.2021.12.002

    Figure Lengend Snippet: Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases CD8-positive ​T cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A) Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D) the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample. * p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).

    Article Snippet: Fluorescent-IHC image acquisition and analysis of co-staining for the pan-macrophage marker F4/80 (1:200 rat polyclonal anti-mouse F4/80, AbD Serotec, Oxford, UK), and the M2 macrophage marker arginase-1 (1:200; rabbit polyclonal anti-arginase-1, GeneTex, Irvine, CA), and separately for the cytotoxic T cell marker CD8 (1:100; rat monoclonal anti-mouse CD8, Novus Biologicals, Centennial, CO), was performed as previously described .

    Techniques: Injection, Staining, MANN-WHITNEY